Skip to main content
    P

    Pfizer Inc (PFE)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $28.88
    -0.01 (-0.03%)

    Market Cap: $164.67B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Pfizer Inc (PFE) Earnings: Report Dates and Results

    Updated Nov 3, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Pfizer (PFE) is expected to report earnings on Feb 1, 2027. In the quarter ended Sep 30, 2026, Pfizer reported EPS of $0.87, above the $0.72 estimate. It beat the EPS estimate in each of the last 23 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    93%(37/40)
    Avg Surprise
    +20.74%
    Streak
    23 Q

    Upcoming Estimates

    Reports Feb 1, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.69
    Range$0.62 - $0.87
    20 analysts
    Revenue Consensus
    $17.37B
    Range$16.25B - $18.80B
    18 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.70
    Range$0.56 - $0.77
    8 analysts
    EPS Estimate DriftChange to current
    90d ago$0.67+4.1%
    60d ago$0.67+4.1%
    30d ago$0.68+3.0%
    7d ago$0.70+0.4%
    Current$0.70
    Revenue Consensus
    $14.12B
    Range$13.80B - $14.43B
    7 analysts

    Next Report

    PFE has an expected report date of Feb 1, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 4.5% above the $0.66 reported for the quarter ended Dec 31, 2025.

    PFE Earnings Call

    The latest PFE earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, PFE beat 37 and missed 3. Revenue for the quarter ended Sep 30, 2026 was $16.58B, down 0.4% from $16.65B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.87$0.72$0.56 - $0.83+20.83%Beat0.0%191 up, 6 downNov 3, 2026$16.58B
    Jun 30, 2026$0.77$0.68$0.61 - $0.76+13.24%Beat-1.3%203 up, 4 downAug 4, 2026$15.03B
    Mar 31, 2026$0.75$0.72$0.56 - $0.81+4.17%Beat-18.5%207 up, 6 downMay 5, 2026$14.45B
    Dec 31, 2025$0.66$0.57$0.44 - $0.68+15.79%Beat+4.8%183 up, 2 downFeb 3, 2026$17.56B
    Sep 30, 2025$0.87$0.63$0.57 - $0.73+38.10%Beat-17.9%171 up, 9 downNov 4, 2025$16.65B
    Jun 30, 2025$0.78$0.57$0.47 - $0.62+36.84%Beat+30.0%187 up, 3 downAug 5, 2025$14.65B
    Mar 31, 2025$0.92$0.67$0.59 - $0.77+37.31%Beat+12.2%152 up, 6 downApr 29, 2025$13.71B
    Dec 31, 2024$0.63$0.46$0.34 - $0.66+36.96%Beat+530.0%171 up, 2 downFeb 4, 2025$17.76B
    Sep 30, 2024$1.06$0.61$0.30 - $0.78+73.77%BeatN/A157 up, 0 downOct 29, 2024$17.70B
    Jun 30, 2024$0.60$0.46$0.27 - $0.59+30.43%Beat-10.4%156 up, 0 downJul 30, 2024$13.28B
    Mar 31, 2024$0.82$0.51$0.37 - $0.82+60.78%Beat-33.3%165 up, 0 downMay 1, 2024$14.88B
    Dec 31, 2023$0.10-$0.18-$0.50 - -$0.09+155.56%Beat-91.2%145 up, 0 downJan 30, 2024$14.57B
    Sep 30, 2023-$0.17-$0.34-$0.48 - -$0.22+50.00%Beat-109.6%120 up, 1 downOct 31, 2023$13.49B
    Jun 30, 2023$0.67$0.58$0.47 - $0.64+15.52%Beat-67.2%173 up, 1 downAug 1, 2023$13.01B
    Mar 31, 2023$1.23$0.99$0.72 - $1.17+24.24%Beat-24.1%164 up, 0 downMay 2, 2023$18.49B
    Dec 31, 2022$1.14$1.04$0.95 - $1.14+9.62%Beat+5.6%164 up, 1 downJan 31, 2023$25.13B
    Sep 30, 2022$1.78$1.40N/A+27.14%Beat+32.8%61 up, 1 downNov 1, 2022$22.64B
    Jun 30, 2022$2.04$1.78$1.54 - $2.18+14.61%Beat+90.7%144 up, 2 downJul 28, 2022$27.74B
    Mar 31, 2022$1.62$1.57$1.01 - $2.36+3.18%Beat+74.2%153 up, 2 downMay 3, 2022$25.66B
    Dec 31, 2021$1.08$0.87N/A+24.14%Beat+157.1%6N/AFeb 8, 2022$23.84B
    Sep 30, 2021$1.34$1.09$0.94 - $1.40+22.94%Beat+86.1%122 up, 0 downNov 2, 2021$24.04B
    Jun 30, 2021$1.07$0.98$0.78 - $1.12+9.18%Beat+37.2%15N/AJul 28, 2021$18.90B
    Mar 31, 2021$0.93$0.78$0.65 - $0.88+19.23%Beat+16.3%14N/AMay 4, 2021$14.52B
    Dec 31, 2020$0.42$0.46$0.38 - $0.59-8.70%Miss-23.6%10N/AFeb 2, 2021$11.43B
    Sep 30, 2020$0.72$0.71$0.60 - $0.79+1.41%Beat-4.0%11N/AOct 27, 2020$10.28B
    Jun 30, 2020$0.78$0.66$0.55 - $0.72+18.18%Beat-2.5%10N/AJul 28, 2020$9.86B
    Mar 31, 2020$0.80$0.73$0.67 - $0.81+9.59%Beat-5.9%10N/AApr 28, 2020$10.08B
    Dec 31, 2019$0.55$0.58$0.54 - $0.59-5.17%Miss-14.1%11N/AJan 28, 2020$1.84B
    Sep 30, 2019$0.75$0.62$0.56 - $0.67+20.97%Beat-3.8%10N/AOct 29, 2019$12.68B
    Jun 30, 2019$0.80$0.75$0.64 - $0.79+6.67%Beat-1.2%10N/AJul 29, 2019$13.26B
    Mar 31, 2019$0.85$0.75$0.66 - $0.81+13.33%Beat+10.4%11N/AApr 30, 2019$13.12B
    Dec 31, 2018$0.64$0.63$0.62 - $0.64+1.59%Beat+3.2%11N/AJan 29, 2019$1.16B
    Sep 30, 2018$0.78$0.75$0.69 - $0.78+4.00%Beat+16.4%14N/AOct 30, 2018$13.30B
    Jun 30, 2018$0.81$0.74$0.72 - $0.77+9.46%Beat+20.9%14N/AJul 31, 2018$13.47B
    Mar 31, 2018$0.77$0.74$0.70 - $0.79+4.05%Beat+11.6%15N/AMay 1, 2018$12.91B
    Dec 31, 2017$0.62$0.56$0.54 - $0.59+10.71%Beat+31.9%17N/AJan 30, 2018$13.70B
    Sep 30, 2017$0.67$0.65$0.63 - $0.66+3.08%Beat+9.8%17N/AOct 31, 2017$13.17B
    Jun 30, 2017$0.67$0.66$0.62 - $0.69+1.52%Beat+4.7%15N/AAug 1, 2017$12.90B
    Mar 31, 2017$0.69$0.67N/A+2.99%Beat+3.0%N/AN/AMay 2, 2017$12.78B
    Dec 31, 2016$0.47$0.51N/A-7.84%Miss-11.3%N/AN/AJan 31, 2017$13.63B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $3.23, up 3.9% from the year before. It was $2.39 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$3.23+3.9%
    Dec 31, 2024$3.11+69.9%
    Dec 31, 2023$1.83-72.2%
    Dec 31, 2022$6.58+48.9%
    Dec 31, 2021$4.42+62.5%
    Dec 31, 2020$2.72-7.8%
    Dec 31, 2019$2.95-1.7%
    Dec 31, 2018$3.00+13.2%
    Dec 31, 2017$2.65+10.9%
    Dec 31, 2016$2.39N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,200 words across 18 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,19718
    2026Q2Jun 30, 20267,84816
    2026Q1Mar 31, 20266,20116
    2025Q4Dec 31, 20259,82523
    2025Q3Sep 30, 20257,72722
    2025Q2Jun 30, 20259,92623
    2025Q1Mar 31, 20253,01716
    2024Q4Dec 31, 20249,41223

    2026Q3 Earnings Call

    Opening remarks

    Francesca DeMartino Chief Investor Relations Officer Good morning, and welcome to Pfizer's earnings call. I am Francesca DeMartino, Chief Investor Relations Officer. On behalf of the Pfizer team, thank you for joining us. This call is being made available via audio webcast at pfizer.com. Earlier this morning, we released our results for the third quarter of 2026 via a press release that is available on our website at pfizer.com. I am joined today by Dr. Albert Bourla, our Chairman and CEO; Cecile Guegan, our CFO; and Chris Boshoff, our Chief Scientific Officer. After their prepared remarks, we will open the call for questions. Members of our leadership team will be available for the Q&A session. Before we get started, I want to remind you that we will be making forward-looking statements and discussing certain non-GAAP financial measures. I encourage you to read the disclaimers in our slide presentation, the press release we issued this morning, and the disclosures in our SEC filings, which are all available on the IR website at pfizer.com. Forward-looking statements on the call are subject to substantial risks and uncertainties, speak only as of the call's original date, and we undertake no obligation to update or revise any of the statements. With that, I will turn the call over to Albert.

    Albert Bourla Chairman and CEO Thank you, Francesca. Good morning, everyone, and thank you for joining our call. I am pleased with another strong quarter for Pfizer. Our excellent commercial execution, including 32% operational revenue growth in the quarter for our launched and acquired products, shows the underlying strength of our business. Financial discipline and ongoing productivity improvement are driving efficiency and contributing favorably to our margins. And with continued progress in our high-value R&D programs, we believe that we are on a pathway to the next stage of meaningful growth. Before going further, I want to welcome Cecile Guegan as our Chief Financial Officer. Cecile brings more than 25 years of finance leadership and the proven ability to deliver new sources of growth. She stood out in a global search for her expertise, her deep knowledge of Pfizer and our industry, and the strategic vision that I believe will help Pfizer unlock sustained long-term value for patients and shareholders. I am looking forward to Cecile's partnership, and I am confident she can help us execute with the discipline and ambition this next chapter requires. Now let me cover several highlights of our progress this quarter. Over the last few years, we have invested close to $80 billion in transactions that have equipped us with key products contributing to current commercial momentum, and platforms with transformative potential. About 80% of this investment was for Seagen, Metsera, and Biohaven.

    Frequently Asked Questions About PFE

    When is Pfizer's next earnings date?

    Pfizer's next earnings report is expected for Feb 1, 2027.

    Did PFE beat earnings estimates last quarter?

    Yes. Pfizer reported EPS of $0.87 for the quarter ended Sep 30, 2026, above the $0.72 estimate, a 20.83% surprise.

    What EPS do analysts expect from PFE next quarter?

    The consensus EPS estimate for Pfizer for the quarter ending Dec 31, 2026 is $0.69 from 20 analysts, with estimates from $0.62 to $0.87.

    How often does PFE beat earnings estimates?

    Pfizer beat the EPS estimate in each of the last 23 quarters, with an average surprise of +32.33%.